Specify a stock or a cryptocurrency in the search bar to get a summary
PepGen Ltd
PEPGPepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts. Address: 321 Harrison Avenue, Boston, MA, United States, 02118
Analytics
WallStreet Target Price
17.4 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures PEPG
Dividend Analytics PEPG
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PEPG
Stock Valuation PEPG
Financials PEPG
Results | 2019 | Dynamics |